Free Trial

Leigh Baldwin & CO. LLC Takes $422,000 Position in Colgate-Palmolive (NYSE:CL)

Colgate-Palmolive logo with Consumer Staples background

Leigh Baldwin & CO. LLC acquired a new stake in shares of Colgate-Palmolive (NYSE:CL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 4,642 shares of the company's stock, valued at approximately $422,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Colgate-Palmolive during the 4th quarter valued at about $26,000. Centricity Wealth Management LLC purchased a new stake in Colgate-Palmolive in the fourth quarter worth about $27,000. Vermillion Wealth Management Inc. purchased a new position in shares of Colgate-Palmolive during the 4th quarter worth approximately $31,000. Union Bancaire Privee UBP SA purchased a new position in shares of Colgate-Palmolive in the 4th quarter valued at approximately $32,000. Finally, Briaud Financial Planning Inc bought a new stake in shares of Colgate-Palmolive during the fourth quarter valued at approximately $32,000. 80.41% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently commented on CL. Citigroup boosted their price objective on shares of Colgate-Palmolive from $103.00 to $108.00 and gave the stock a "buy" rating in a research note on Monday, April 28th. Piper Sandler decreased their price objective on shares of Colgate-Palmolive from $108.00 to $107.00 and set an "overweight" rating for the company in a report on Monday, March 31st. Raymond James reaffirmed an "outperform" rating and set a $105.00 price target (down from $110.00) on shares of Colgate-Palmolive in a report on Monday, February 3rd. Wells Fargo & Company upped their price objective on Colgate-Palmolive from $83.00 to $88.00 and gave the stock an "underweight" rating in a report on Wednesday, April 2nd. Finally, UBS Group boosted their price target on shares of Colgate-Palmolive from $105.00 to $109.00 and gave the stock a "buy" rating in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Colgate-Palmolive currently has an average rating of "Hold" and an average price target of $102.12.

Read Our Latest Stock Report on CL

Colgate-Palmolive Trading Up 1.0%

Shares of NYSE:CL traded up $0.96 during trading on Friday, reaching $93.26. 1,510,872 shares of the stock were exchanged, compared to its average volume of 5,312,610. Colgate-Palmolive has a 12-month low of $85.32 and a 12-month high of $109.30. The firm has a market cap of $75.58 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 4.20 and a beta of 0.39. The company has a debt-to-equity ratio of 13.40, a quick ratio of 0.58 and a current ratio of 0.92. The firm's 50-day moving average price is $91.95 and its 200 day moving average price is $91.26.

Colgate-Palmolive (NYSE:CL - Get Free Report) last issued its quarterly earnings data on Friday, April 25th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.86 by $0.05. The firm had revenue of $4.91 billion during the quarter, compared to analyst estimates of $4.92 billion. Colgate-Palmolive had a return on equity of 477.77% and a net margin of 14.38%. Colgate-Palmolive's quarterly revenue was down 3.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 EPS. On average, sell-side analysts anticipate that Colgate-Palmolive will post 3.75 earnings per share for the current fiscal year.

Colgate-Palmolive Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, May 15th. Investors of record on Thursday, April 17th were paid a dividend of $0.52 per share. This is an increase from Colgate-Palmolive's previous quarterly dividend of $0.50. This represents a $2.08 dividend on an annualized basis and a yield of 2.23%. The ex-dividend date was Thursday, April 17th. Colgate-Palmolive's dividend payout ratio is presently 58.76%.

Colgate-Palmolive announced that its Board of Directors has initiated a stock repurchase program on Thursday, March 20th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company's management believes its shares are undervalued.

About Colgate-Palmolive

(Free Report)

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.

Featured Stories

Institutional Ownership by Quarter for Colgate-Palmolive (NYSE:CL)

Should You Invest $1,000 in Colgate-Palmolive Right Now?

Before you consider Colgate-Palmolive, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Colgate-Palmolive wasn't on the list.

While Colgate-Palmolive currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Analysts Are Watching These 4 Penny Stocks—You Should Too
Congress Is Pouring Millions Into These 6 Surprising Stocks
3 Dirt-Cheap Stocks in a Market That’s Getting Expensive

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines